The hereditary hemochromatosis (HHC) gene, HFE on chromosome 6p21.3, encodes a protein involved in iron homeostasis. HFE mutations have low penetrance with a mild effect on serum iron levels. Animal, twin, and population studies have shown that carrier state for C282Y can increase iron levels. A proportion of heterozygotes show slightly elevated serum iron levels. Increased serum iron has been suggested to increase the risk for oxidative damage to DNA. Epidemiologic studies established a correlation between iron levels and cancer risk.
Hereditary hemochromatosis (HHC) is a common autosomal recessive iron overload disease (OMIM 235200). 1 Because iron accumulation in vital organs and subsequent damage takes a long time, the clinical onset is usually at or after middle age. Traditionally, the disease has been diagnosed by assessment of the biochemical iron parameters (serum iron and ferritin levels, transferrin saturation). The gene responsible for the majority of HHC cases has been identified as the HFE gene on chromosome 6p21.3. 2 The use of molecular testing in predictive diagnosis has been problematic because of the lack of strong phenotype-genotype correlation. 1, [3] [4] [5] [6] Recent efforts have defined genetic heterogeneity for hereditary forms of iron overload and identified most of the genes responsible. 7, 8 Besides autosomal recessive classic HHC, other forms of hereditary iron overload exist ( Table 1) . The features and molecular genetics of non-HFE hemochromatosis are reviewed elsewhere. [7] [8] [9] The genes responsible for African (OMIM 601195) and neonatal (OMIM 231100) iron overload are still unknown (neonatal iron overload may be an alloimmune condition rather than genetic 10 ). The importance of the genetic heterogeneity is that it may have caused misclassification error and, subsequently, some of the discrepancies in phenotype-genotype correlation in earlier HHC research.
Low penetrance of C282Y in causation of clinical HHC has been established by linkage 30 and molecular studies [3] [4] [5] [31] [32] [33] [34] [35] [36] [37] (see review 6 ). Specifically, some population-based mass screenings have shown that Ͻ 1% of homozygotes develop frank clinical hemochromatosis. [35] [36] [37] It may be that expression of C282Y as a clinical disorder requires the participation of other genes or environmental factors.
GENE VARIANTS
Originally, two missense alterations were identified in the HFE gene that occur at high frequencies in HHC patients and in the general population: a G to an A at nucleotide 845 of the original mRNA sequence (GI:1469789) in the amino acid codon 282 in exon 4 (C282Y), and a C to a G at nucleotide 187 in the same sequence in the amino acid codon 63 in exon 2 (H63D). A third missense mutation in exon 2 (nucleotide 193 in the mRNA sequence), S65C, has recently been identified that may contribute to the development of a mild form of HHC. 38, 39 Adherence to the above nucleotide numbers in description of these mutations is common practice but conflicts with the current principles of nomenclature. Acceptable unequivocal description of these three HFE mutations is shown in Table 2 .
The total number of HFE variants detected to date is at least 37, of which 19 are missense 11, 29 (see also The Human Gene Mutation Database). The most common mutation is C282Y. The cysteine at position 282 within the immunoglobulin domain constant region takes part in a critical disulfide bond. The C282Y mutation abolishes cell surface expression by preventing the association of the HFE gene product with beta-2 microglobulin. 40 The second most common mutation H63D results in measurable consequences on hepatic iron levels in mice 41 but does not cause HHC even in homozygous form in humans because of low penetrance and delayed action. 34, 42, 43 In combination with a trans C282Y mutation, however, H63D can cause HHC. 42 The compound heterozygosity for C282Y and H63D shows its effect on iron parameters at a level between C282Y homozygosity and C282Y heterozygosity. 34, 44, 45 The C282Y mutation causes HHC as a result of a deficiency of the HFE protein (loss-of-function) not by changing its function (gain-of-function) or cellular location. There is no sign of haploinsufficiency caused by heterozygous C282Y mutation. 43 Toomajian and Kreitman 46 have conducted a comprehensive study of variation of the HFE gene on 60 chromosomes from three continents. They found a total of 41 polymorphic sites forming 18 distinct haplotypes in the 11,214-bp region including the flanking regions. Some of these polymorphic sites are in the 3' untranslated region of the gene and could conceivably affect mRNA stability or levels of protein translation. Other known polymorphisms in the 5' flanking region 47 or in intron 3 48 do not influence serum iron indices. Functionally important mutations of HFE and other iron-related genes have been listed in a recent publication. 29 A number of genotyping methods have been used to type HFE variants. The most popular method is polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. 49 A multiplex PCR-RFLP method can type the two most common mutations in a single assay. 50 A comprehensive diagnostic assay for nonsynonymous changes in HFE and mutations in some of the other iron metabolism regulatory genes using PCR-sequence specific primer (PCR-SSP) method has been developed. 11 Kits for exhaustive HFE typings using reverse hybridization-based strip assay are available. 51 Other methods include real-time PCR, 52 SSCP, 53 heteroduplex analysis, 54 and denaturing HPLC. 55 
POPULATION FREQUENCIES
Population frequencies of HFE gene variants for geographic regions and ethnic groups have been presented in another 24 ; e S142G polymorphism interacts with C282Y in genetic associations with cancer susceptibility [25] [26] [27] but no effect on HHC. 28 Functionally important mutations of iron storage disease genes are reviewed elsewhere. 29 
Table 2
Three most common HFE sequence variants HuGE review 1 and in more recent reports. 34, 56 In brief, the C282Y mutation is confined to populations of European origin and is most common in Northern Europe where the heterozygote frequency is 10% to 20%. 57 
DISEASE
Childhood leukemias are rare diseases. Only 1 in 100 new cancers is a childhood cancer and approximately 25% of childhood cancers are leukemias. Nearly 80% of childhood leukemias are acute lymphoblastic leukemia (ALL). Childhood ALL has been associated with prenatal exposure to ionizing radiation, certain chromosomal abnormalities, infections and an aberrant immune response to them, socioeconomic status, maternal and perinatal factors, various environmental exposures, and parental occupational history, but the actual causes are largely unknown. 58 -60 Childhood leukemia is not inherited. It is more likely that genetic susceptibility increases the risk of an environmental exposure. 61 Molecular epidemiologic studies identified a number of genetic associations, mainly with genes encoding xenobiotic and DNA repair enzymes. 62, 63 Another group of genes showing associations with childhood ALL are human leukocyte antigen (HLA) genes with a yet unknown biological mechanism. 64 -66 One of the most consistent findings in leukemia epidemiology is the increased male-to-female ratio. 60, 67 Some genetic association studies have also found gender-specific associations 62, 64, 66 including the HFE association. 68 It appears that males may have a lower threshold for genetic factors to exert their effect. The multifactorial threshold model for pyloric stenosis is similar in that males have a lower threshold to be affected with the disease. 69, 70 Why "maleness" lowers the liability threshold in leukemia is unknown but possible reasons include an epigenetic one as postulated for autism. 71 ASSOCIATIONS HFE is one of the molecules that participate in iron homeostasis. It has been postulated that its main role is in iron transport across the cell membrane including the regulation of absorption in the gastrointestinal tract. 72 Wild-type HFE reduces the affinity of transferrin receptor for transferrin-bound iron, 73 comigrates with it inside the cell, 74 and regulates cellular uptake of iron from transferrin within endocytic compartments. 75 When its expression is hampered, the interactions with transferrin receptor on the cell surface and with transferrin inside the cell do not occur and iron influx is increased. Despite these findings, it is possible that it has a more important role in controlling expression of hepcidin (encoded by HAMP), which has a regulatory role in downregulating the intestinal iron absorption, placental transport of iron, and the release of iron by macrophages. 9, 16 A twin study identified a considerable "additive" genetic component in body iron level regulation. Within that component, the share of HFE mutations was less than one would expect. 76 The small share of HFE variation in total heritability has been confirmed in a population-based study. 77 A study of sib-pairs homozygous for C282Y showed significant variation in iron overload between siblings. 3 These findings attribute a larger role to other genes involved in iron absorption, transport, and storage. Two such genes, HAMP and HFE2, have been shown to modify the expression of C282Y homozygosity in HHC. 13, 15, 17 The expression of C282Y mutation, in homozygous or heterozygous form, may require genetic modifiers and environmental interactions to have an effect on body iron content.
Although not usually causing HHC, heterozygosity for C282Y may also be relevant in disease susceptibility other than HHC. On average, 1 in 10 individuals in European populations may be heterozygous for the C282Y mutation. 1, 34, 49, 56 This is a frightening frequency if carriers of this mutation are in any way vulnerable to any disease.
A study of 1058 heterozygotes ascertained from 202 pedigrees by family HLA typing revealed that serum iron and ferritin concentrations and transferrin saturation values generally overlapped with the normal range but were higher in 15% to 25% of heterozygotes. 78 Although mean transferrin saturation in C282Y heterozygotes is only slightly elevated, the magnitude of elevation was similar to that reported as a risk factor for cancer in cohort studies. 79 The findings of the study by Bulaj et al. 78 corroborate with those of other family-or population-based studies. In most studies, up to 25% of heterozygotes have minor subclinical iron status changes. 31-34,80 -88 In general, the population studies show a small but significant increase in transferrin saturation and a small but usually insignificant increase in serum ferritin. HFE heterozygosity has been confirmed as one of the genetic factors affecting body iron content also in a twin study. 76 A meta-analysis of 14 studies concluded that C282Y heterozygosity is associated with a 4-fold risk of increased iron stores (95% confidence interval ϭ 2.9 to 5.8), although the reliability of this result was low due to heterogeneity. 44 In a minority of patients with HHC, heterozygosity for C282Y may even be the only mutation detectable out of the three major HFE mutations. 31 An animal study showed that C282Y heterozygosity is capable of increasing iron levels. 89 Another animal study noted the importance of genetic background in the expression of HFE mutations. 90 Ethnicity may be a modifier in association studies because of the variation in other genes involved in iron homeostasis. To date, only one study has suggested higher penetrance for H63D in Hispanics 5 but this finding needs replication. The overall conclusion is that heterozygosity for the C282Y mutation of HFE may increase serum iron levels in a subset of carriers. Similar to C282Y heterozygosity, a very mild effect of S65C mutation on iron overload has also been noted. 91 The associations described later are most likely the result of serum iron elevation in heterozygotes.
Association of iron levels with cancer
Increased risk for cancer in subjects with even moderately elevated serum iron levels has been shown repeatedly. Prospective cohort studies including between 6,000 and 174,000 sub-jects have reported a link between indicators of high iron stores and increased relative risk for cancer in general. 79, [92] [93] [94] [95] [96] [97] These studies include the first and second National Health and Nutrition Examination Surveys. Additional case-control studies revealed the same link in colon 98 and liver cancer. 99, 100 Some studies yielded negative results in gastric 101 and epithelial cancers. 102 The link between increased body iron and cancer was also suggested by the decreased cancer incidence in regular blood donors in Sweden. 103 Increased intracellular iron can influence the process of carcinogenesis by catalyzing the formation of mutagenic hydroxyl radicals, by acting as an essential nutrient for proliferating neoplastic cells, or by its deleterious effects on the immune system. 104 -106 One of the immune disturbances in iron overload is the higher average CD4:CD8 ratios,and this is not related to the mutations in HFE but directly to iron. 107 The evidence for a procarcinogenic role of iron is presented in Table 3 .
As the major site of iron storage, the liver is most sensitive to iron overload. As a result, liver cancer risk secondary to cirrhosis is enormously increased in HHC and the risk is also increased in non-HHC iron overload (see Table 3 ). In a study of 230 patients and 230 controls with noniron-related chronic liver diseases, the increased risk for extra hepatic cancers in HHC showed no correlation with HFE genotype, indicating that it is iron itself but not HFE that confers risk for cancer. 130 HHC is not the only oxyradical overload disease. Another hereditary disease characterized by intracellular copper overload, Wilson disease (OMIM 277900), also shows increased longterm risk with internal malignancies including hepatoma. 131 Higher expression of biomarkers for oxidative stress and increased frequency of P53 tumor suppressor gene have been observed in both oxyradical overload diseases. 132 More frequent spontaneous and radiation-induced chromosomal damage in HHC 133 may be an important mechanism for cancer development in iron overload. Although not a uniform finding, several studies reported an increased risk for extrahepatic cancer in HHC. 124, 130 Association of HFE with leukemia and lymphoma An earlier study found an increased risk for cancer in obligatory heterozygotes for the putative HHC gene. 134 The association with hematologic malignancies was restricted to males. After the discovery of HFE as the HHC gene, 2 a number of studies have investigated C282Y and H63D mutations in different cancers. The first ones were conducted by Beckman et al. [25] [26] [27] who found an increased frequency of C282Y mutation in multiple myeloma, breast, colorectal, and liver cancers, but only in interaction with the S142G (g.424AϾG) polymorphism of TFRC. Since then, C282Y associations have been reported in colon 135 and breast cancer 136 and an H63D association in malignant glioma. 137 Two studies did not find any increase in C282Y frequency in colon cancer. 138, 139 One study investigated the HFE mutations in a series of cancers and did not find a generally increased frequency. 140 We have recently determined the C282Y frequency in 147 cases with human immunodeficiency virus (HIV)-induced Kaposi sarcoma and their HIV and 147 human Kaposi sarcoma herpes virus (KSHV) doublepositive matched controls all from the Multicenter AIDS Cohort Study (MACS). 141 We did that because of the suggestion that iron is involved in the pathogenesis of classic Kaposi sarcoma. 142 The matched pair analysis by conditional logistic regression yielded an odds ratio of 5.4 (95% CI ϭ 1.8 to 16.4; P ϭ 0.0009). The mutation frequency was 14.5% in cases (all heterozygous) and 3.0% in matched-controls. It is unknown whether C282Y is associated with cancers because of its effect on body iron content or linkage disequilibrium (LD) with another gene. The Kaposi sarcoma study also investigated the HLA complex and endothelin-1 gene (EDN1) on either side of HFE (M.T. Dorak et al., manuscript in preparation, 2005). The C282Y association was independent of the other associations found with EDN1 and HLA genes.
HFE associations have been sought also hematologic malignancies (Table 4) . We reported the C282Y frequencies in childhood acute lymphoblastic leukemia (ALL). 68 In a case-control study of Welsh and Scottish patient groups, there was an increase in C282Y mutation frequency compared to newborns from respective newborn controls but in males only. The association mainly concerned heterozygosity for C282Y. H63D was examined only in the larger Scottish group and did not seem to contribute to leukemia susceptibility. Recent detailed work ruled out LD with EDN1 and several HLA complex loci as the reason for this association. 143 There is one other published report on the C282Y mutation in childhood leukemia from Finland. 148 In a study of 232 mainly adult patients with various hematologic malignancies, 32 patients with childhood ALL (14 boys) did not have an increased frequency of C282Y. The Finnish study did not find an increased frequency in any of the subsets (n ϭ 15 to 53). In another study of 36 Spanish patients with adult acute myeloid leukemia and 108 controls, the frequencies for C282Y and H63D were not different between cases and controls. 145 Both these studies appear to have shown negative results but obviously they were underpowered to detect significant differences. Notably, the two studies that have shown an association in childhood leukemia are British studies and to what extent this finding can be generalized to other populations is currently unknown.
Other studies of HFE associations in hematologic malignancies included our own adult Hodgkin disease case-control study, 144 which revealed no association; and a myelodysplastic syndrome study in Hungary with a positive association, 146 which could not be replicated in Greece. 147 In the breast cancer study performed in Tennessee, the cases included patients with hematologic malignancies transplanted in the same center. 136 The C282Y frequency in this subset was 17.0% (n ϭ 129) compared with local (12.7%, n ϭ 118) and national (12.4%, n ϭ 2016) mutation frequencies, which appears to be increased.
All HFE-cancer association studies reported to date are casecontrol studies that have recognized limitations. Chance associations cannot be ruled out-even with replication-until functional studies identify the biological mechanism of the reported associations.
Possible mechanism of leukemia association
In other cancers associated with C282Y, statistical interactions with a TFRC allele, [25] [26] [27] increased iron intake in diet and older age, 135 and correlation between C282Y gene dosage and body iron stores in breast cancer 136 strongly argue that the mechanism of the HFE associations with cancer is related to iron. Thus, molecular HFE association studies seem to complement the effect of elevated iron on cancer risk. The question that whether the same risk applies to a childhood cancer has not been tested experimentally.
HFE is expressed by lymphoid as well as myeloid cells. In a B-lymphoid cell line homozygous for C282Y and analyzed in detail, iron uptake is increased and cell sensitivity to oxidative stress is enhanced. 149 This sensitivity to oxidative stress is crucial in iron-induced carcinogenesis. 104 -106,108 -110 Chronically increased oxidative stress from elevated levels of iron in the body may increase radiation sensitivity by decreasing cellular oxygen radical scavenging capability. Low-level radiation sensitization by iron, which can occur in lymphocytes, has been proposed to increase cancer susceptibility, 150, 151 and heterozygosity for HFE mutations has been emphasized as a risk factor. 152, 153 Given the higher sensitivity to environmental exposures during early development, C282Y heterozygote fetuses, especially if their mothers are the origin of their mutation, may be subject to higher intracellular iron levels in their lymphoid cells. This may have a promoter effect if a lymphoid cell has leukemic transformation spontaneously or due to environmental exposure. Unlike adult cancers, no link has been investigated between body iron stores and childhood cancer, but in neuroblastoma, Hodgkin disease, and ALL, an unfavorable effect of increased iron stores has been shown on survival. 154 -156 There is a putative link between viral infection and childhood ALL. 58, 157 Elevated iron levels in lymphoid cells may be relevant in this context because iron favors viral infections in animals. 113, 114 Damage caused by iron overload in internal organs takes years, and is sex-and age-dependent. The proposed mechanism for childhood ALL entails increased intracellular iron levels in lymphoid cells during development. If iron contributes to childhood ALL susceptibility, other genes with roles in iron metabolism (Table 1) are expected to show associations. This can be investigated in incident case studies of childhood leukemia and other cancers to separate the effects of iron from a genetic association secondary to LD with C282Y mutation.
At present, all cancer and leukemia associations with HFE are no more than statistical associations. Assuming they are real, an alternative mechanism to be explored is other genes around the HFE locus. Several candidates already exist. 144 f comparison of H63D mutation frequencies between cases and controls yielded an OR of 1.87 (95% CI ϭ 0.95 to 3.68, Fisher's P ϭ 0.08-our calculation);
g ORs vary for each subset with n ϭ 5 to 13; h our calculation.
Among those, EDN1 is a strong one to be responsible for the C282Y association through LD. Although our preliminary study of EDN1 in childhood ALL showed a weak but independent association with no LD with C282Y, 143 a more comprehensive study is required to rule out the involvement of neighboring genes and even other variants of HFE in C282Y association.
Association of HFE with nonmalignant diseases
Besides HHC, associations have suggested that the HFE mutations may also be involved in the development of other nonmalignant diseases. These include cardiovascular diseases, diabetes, arthritis, neurodegenerative disorders, and alcoholic liver disease. 45, 158 Most of these associations, however, have been inconsistent. A list of conditions showing genetic associations with HFE is being compiled at the NCBI Genetic Associations Database.
It has to be underlined that none of the disease associations suggests a uniformly deleterious effect of C282Y mutation. If this was the case, one would expect a negative association between C282Y and longevity. Despite an early suggestion, latest studies conclusively ruled out an age-related decline in C282Y frequency. 56, 159 More comprehensive studies taking into account genetic and environmental interactions are needed to conclude whether a subgroup of HFE mutation carriers has higher rates of disease and what additional factors identify that subset.
INTERACTIONS
Only one gene-gene interaction, between HFE and TFRC in multiple myeloma, 25 and no gene-environment interaction has been investigated in hematological malignancies. In iron overload, however, a number of factors in addition to HFE mutations affect the severity. In the most extreme example of Hfe knockout mice, the strain of mice determines the amount of iron in the liver. 160 HAMP 17 and TFRC gene polymorphisms, [25] [26] [27] mitochondrial DNA mutations, 161 parent-of-origin, 78 and environmental factors (including pregnancy, regular blood loss, iron intake, hepatitis B and C, and alcohol) have been suggested to interact with C282Y in its associations with diseases or in its effect on biochemical parameters of iron stores. 1, 6, 9, 76, [162] [163] [164] The P570S polymorphism of the transferrin gene shows an epistatic interaction with C282Y as a risk marker for Alzheimer disease. 24 This variant of TF has not been examined in biochemical iron overload states.
Phenotypic expression of HHC is affected by the presence or absence of the telomeric HLA ancestral haplotype characterized by HLA-A*03, D6S265-1, and D6S105-8. 165, 166 Patients bearing this haplotype tend to have more severe forms of HHC, and this effect is dependent on gene dosage. 81, 167, 168 However, this has not been a universal finding. 169 Because of the effects of the ancestral haplotype on disease phenotype, HFE association studies in other diseases need to cover the area between HLA-A and HFE. This may have some bearing on the different results for the same genetic association in different populations.
GAPS AND RESEARCH PRIORITIES
Leukemia and lymphoma associations with HFE have not been sufficiently studied. Available studies are relatively small case-control studies.
Definitive studies are needed
Given the population frequency of common HFE variants and potential implications of any disease association on public health, there is need for a definitive study on HFE associations in hematopoietic cancers and especially for their mechanisms. Despite the rarity of childhood leukemias, Children's Oncology Group in USA and United Kingdom Childhood Cancer Study Group have been collecting large numbers of samples through nationwide recruitments. However, it is also important to perform association studies in other ethnic groups. Given the strong effect modification by sex, even comparison of male patients with female patients (without controls) may provide clues whether the male-specific HFE association can be confirmed in large prospective incident case studies.
Other iron-related genes need to be tested
The influence of HFE on body iron stores is small. If an iron-related mechanism is operating, variants of other genes taking part in iron homeostasis should also show associations. This is particularly important in geographic regions where HFE variants have small frequencies.
Possible gene-gene interactions should be addressed
An interaction between HFE and another gene in the region between HFE and HLA-A may explain the ancestral haplotype effect on HHC phenotype observed in some studies. Similarly, the HFE gene itself should be thoroughly examined especially in its regulatory regions. Interactions with the known polymorphisms of other genes such as TFRC (424A), HAMP (R59G, G71D, or R56X), and HFE2/HJV (S105L, E302K, N372D, R335Q, L101P, G320V) that have an effect on iron status are important ones. No cancer association studies with HFE concurrently examined the genes encoding antioxidant enzymes. Cellular antioxidant defense mechanisms against prooxidant states include enzymes such as superoxide dismutase, catalase, and glutathione systems. 104, 170 Given the antipromoter and anticarcinogen activity of antioxidant defenses, 171, 172 deleterious effect of iron would be greater in states of reduced antioxidant reserve. The genes for these enzymes have known functional polymorphisms 170 and these may also interact with HFE mutations to increase susceptibility to leukemia.
Gene-environment interactions require attention
Exposure to environmental iron during pregnancy or early childhood may interact with HFE variants in determination of leukemia susceptibility. A gene-environment interaction may also be shown with routine iron supplementation during pregnancy except when indicated for iron deficiency. In light of other genetic effect modifiers of common exposures, 173 exam-
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ination of an interaction between maternal iron intake and the presence of C282Y in the offspring may be a worthwhile effort.
Parent-of-origin effect has not been studied
The association with childhood ALL may have to do with intrauterine environment if it is due to the generally increased sensitivity of developing child (from fetus to prepuberty) to environmental assaults. 174 It is a possibility that the association may be restricted to C282Y carriers who have inherited it from their mothers and whose intrauterine environment had elevated levels of iron because of heterozygosity in mothers.
A large case-control study that would carefully construct the functionally relevant haplotypic variants of the HFE gene, examine selected other genes involved in iron metabolism with incorporation of appropriate questionnaire data on iron supplementation and dietary habits is going to be an appropriate first step to fill the gap of knowledge outlined above, especially when conducted where the evidence appears to be strongest for childhood leukemia association. A prospective family-based association study can achieve the same purpose while providing additional information on the question of parent-of-origin effect.
CONCLUSIONS
The male-specific association of C282Y with childhood ALL in two populations seems to have generated useful hypotheses that can be tested. Currently available evidence suggests that this association with leukemia susceptibility arises from its effect on body iron levels. The sex-dependent penetrance of C282Y is age-dependent and cannot explain the male-specificity of the C282Y association in childhood. The presence of other male-specific genetic associations with childhood leukemia brings about the possibility of an additive role for these susceptibility markers over and above the risk conferred by "maleness" in a multifactorial threshold model. While what makes maleness a risk factor in genetic terms is studied, the HFE-associated susceptibility to childhood leukemia will have to be elaborated by extending the association studies to other iron-related functional genes and by taking into account gene and environment interactions. The C282Y association in leukemia and other cancers may highlight the need to focus on the known connection between iron and cancer in which HFE plays only a limited role. The very high frequency of C282Y in European populations does not mean that we are dealing with a problem restricted to Europe and America. If this association is due to elevated iron levels at biochemical level, the implications on the risks being inflicted by food-iron fortification programs, uncontrolled supplemental iron intake, and routine iron prescription in pregnancy will be worldwide.
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